UNSPSC 51282316: Erythromycin estolate

This classification denotes a macrolide antibiotic with the molecular formula C40H71NO14.C12H26O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XRJ2P631HP, chemically known as erythromycin, n-demethyl-n-(methyl-11c)- but more generally known as erythromycin estolate, which bears US NIH Compound Identifier 12560. European Medicines Agency schedules Erythromycin estolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01941MIG.

UNSPSC 51282316 Erythromycin estolate is a Commodity code that nominally covers a specific macrolide antibiotic pharmaceutical, but recent state and local procurement activity under this code shows little relevant purchasing. The two opportunities tagged to this code in the recent posting record do not align with erythromycin estolate procurement: one is a completed piggyback pharmaceutical warehouse award by the Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (awarded to Chartwell Rx LLC on August 28, 2026, for $2,999,999.11 over the contract life including renewal periods), and the other is an open invitation for bid from Seminole County, Florida for naloxone and safe drug deactivation systems posted June 30, 2026 with a response deadline of July 26, 2023. Neither solicitation involves erythromycin estolate or narrow-spectrum macrolide antibiotics as a primary procurement vehicle.

The geographic footprint of recent postings is limited to Illinois and Florida, and the issuing bodies are a state health department and a county government. No standout repeat buyers appear in the record. Given the mismatch between the code's nominal scope and the actual recent opportunities tagged to it, vendors should verify whether erythromycin estolate-specific procurement opportunities appear in their target state or local jurisdictions' published RFP and IFB pipelines before committing resources to pursue this code.